BioAge Labs (NASDAQ:BIOA) Trading 4.6% Higher – Here’s Why
by Jessica Moore · The Cerbat GemBioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) traded up 4.6% during trading on Tuesday . The company traded as high as $16.08 and last traded at $16.04. 105,106 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 619,233 shares. The stock had previously closed at $15.34.
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Citigroup boosted their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Piper Sandler assumed coverage on BioAge Labs in a report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday. BTIG Research assumed coverage on BioAge Labs in a report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Morgan Stanley set a $23.00 price target on BioAge Labs in a report on Wednesday, February 4th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.00.
Check Out Our Latest Research Report on BioAge Labs
BioAge Labs Stock Up 3.9%
The business has a 50 day moving average of $17.90 and a 200 day moving average of $16.05. The company has a market capitalization of $744.09 million, a P/E ratio of -6.97 and a beta of 0.99.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The company had revenue of $2.77 million during the quarter. On average, research analysts anticipate that BioAge Labs, Inc. will post -2.59 EPS for the current year.
Hedge Funds Weigh In On BioAge Labs
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stempoint Capital LP bought a new position in BioAge Labs during the first quarter valued at approximately $5,923,000. Janus Henderson Group PLC boosted its stake in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Quantinno Capital Management LP bought a new position in BioAge Labs during the first quarter valued at approximately $404,000. Octagon Capital Advisors LP boosted its stake in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of BioAge Labs by 653.2% in the 1st quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after purchasing an additional 120,188 shares during the last quarter.
About BioAge Labs
BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.
At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.